Patient Profile 3: A 62-Year-Old Woman with Colon Cancer
Arvind N. Dasari, MD, MS, presents the third patient profile of the discussion, a 62-year-old woman with colon cancer, highlighting the role of MRD testing in guiding treatment decisions in the surveillance setting.
EP: 1.Testing for MRD With ctDNA in Colorectal Cancer (CRC)
EP: 2.Platforms for Testing MRD in CRC
EP: 3.MRD Testing Practices in Colorectal Cancer
EP: 4.Patient Profile 1: A 50-Year-Old With Stage III Colorectal Cancer
EP: 5.Prospective Trial Data on MRD Testing in Early-Stage CRC
EP: 6.COSMOS-CRC-03: ctDNA and Recurrence in Colorectal Cancer
EP: 7.Patient Profile 2: A 39-Year-Old Woman with High-Risk Stage II CRC
EP: 8.DYNAMIC Trial: ctDNA Analysis Guiding Adjuvant Therapy in Early-Stage CRC
EP: 9.Colorectal Cancer: Key Updates from GALAXY At ASCO GI 2024
EP: 10.Rationale and Study Design of CIRCULATE-NORTH AMERICA in CRC
EP: 11.Initial Results from Phase 2 COBRA Study in Colorectal Cancer
Now Viewing
EP: 12.Patient Profile 3: A 62-Year-Old Woman with Colon Cancer
EP: 13.The Study Design and Early Findings from the INTERCEPT Study in CRC
EP: 14.BESPOKE CRC: The Impact of ctDNA-Guided Therapy in CRC
EP: 15.Future Perspectives on MRD Testing in Colorectal Cancer
Recent Videos
Related Content
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024Article
The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
